Search results for " left ventricular hypertrophy"

showing 10 items of 22 documents

Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: A role for organ damage markers

2012

BACKGROUND: Cardiovascular risk assessment in the clinical practice is mostly based on risk charts, such as Framingham risk score and Systemic Coronary Risk Estimation (SCORE). These enable clinicians to estimate the impact of cardiovascular risk factors and assess individual cardiovascular risk profile. Risk charts, however, do not take into account subclinical organ damage, which exerts independent influence on risk and may amplify the estimated risk profile. Inclusion of organ damage markers in the assessment may thus contribute to improve this process. OBJECTIVE: Our aim was to evaluate the influence of implementation of SCORE charts with widely available indexes of organ damage, with t…

cardiovascular riskmedicine.medical_specialtyestimated glomerular filtration ratemicroalbuminuriaPhysiologyCardiovascular risk organ damage markersCoronary DiseaseLeft ventricular hypertrophyRisk Assessmentmetabolic syndromecardiovascular risk; estimated glomerular filtration rate; left ventricular hypertrophy; metabolic syndrome; microalbuminuria; prevention; score; target organ damagepreventiontarget organ damageSCOREInternal MedicineMedicineHumansAlbuminuriaRisk factorIntensive care medicineEstimationFramingham Risk Scorebusiness.industryMetabolic Syndrome XBiomarkermedicine.diseaseSurgeryleft ventricular hypertrophyAlbuminuriaMicroalbuminuriamedicine.symptomMetabolic syndromebusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersGlomerular Filtration RateHuman
researchProduct

Ventricular-vascular coupling in hypertension: methodological considerations and clinical implications.

2014

The present review is addressed to analyse the complex interplay between left ventricle and arterial tree in hypertension. The different methodological approaches to the analysis of ventricular vascular coupling in the time and frequency domain are discussed. Moreover, the role of hypertension-related changes of arterial structure and function (stiffness and wave reflection) on arterial load and how ventricular-vascular coupling modulates the process of left ventricular adaptation to hypertension are analysed.The different interplay between vascular bed and left ventricle emerges as the pathophysiological basis for the development of the multiple patterns of ventricular structural adaptatio…

Ventricular-vascular couplingmedicine.medical_specialtyWave reflectionHeart VentriclesLeftDiastoleBlood PressureLeft ventricular hypertrophyPulse wave analysisVentricular Function LeftInput impedanceVascular StiffnessEffective arterial elastanceInternal medicinemedicineVentricular FunctionHumansArterial stiffness; Effective arterial elastance; Hypertension; Input impedance; Left ventricular hypertrophy; Pulse wave analysis; Therapy; Ventricular-vascular coupling; Wave reflection; Aorta; Arteries; Blood Pressure; Elasticity; Heart Ventricles; Humans; Hypertension; Vascular Stiffness; Ventricular Function Left; Cardiology and Cardiovascular Medicine; Medicine (all)AortaArterial structureVentricular functionbusiness.industryMedicine (all)Left ventricular hypertrophyarterial stiffness effective arterial elastance hypertension input impedance left ventricular hypertrophy pulse wave analysis therapy ventricular–vascular coupling wave reflectionGeneral MedicineArteriesmedicine.diseaseArterial stiffnessSettore MED/11 - Malattie Dell'Apparato CardiovascolareArterial treeElasticitymedicine.anatomical_structureVentricleHypertensionCardiologyTherapybusinessCardiology and Cardiovascular MedicineVentricular vascular couplingJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct

Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men

2013

Background and aim: Experimentally uric acid may induce cardiomyocyte growth and interstitial fibrosis of the heart. However, clinical studies exploring the relationship between serum uric acid (SUA) and left ventricular (LV) mass yielded conflicting results. The aim of our study was to evaluate the relationships between SUA and LV mass in a large group of Caucasian essential hypertensive subjects. Methods and results: We enrolled 534 hypertensive patients free of cardiovascular complications and without severe renal insufficiency. In all subjects routine blood chemistry, including SUA determination, echocardiographic examination and 24 h ambulatory blood pressure (BP) monitoring were obtai…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureEndocrinology Diabetes and MetabolismHeart VentriclesPopulationLeft ventricular maMedicine (miscellaneous)Blood PressureLeft ventricular hypertrophyEssential hypertensionWhite PeopleEssential hypertensionBody Mass Indexchemistry.chemical_compoundSerum uric acidInternal medicinemedicineHumansEssential hypertension; Serum uric acid; Cardiovascular risk; Left ventricular mass; Left ventricular hypertrophyeducationeducation.field_of_studyCreatinineNutrition and Dieteticsbusiness.industryLeft ventricular hypertrophyBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseCardiovascular riskUric AcidEndocrinologyBlood pressureCross-Sectional StudieschemistryBlood chemistryEchocardiographyCreatinineHypertensionCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment

2016

Cardiorenal syndrome type 4 (CRS type 4), or chronic renocardiac syndrome, has been defined as "chronic abnormalities in renal function leading to cardiac disease" and recognizes the extreme burden of cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Even though the treatment for CVD has dramatically improved over the past decades, it still takes responsibility for up to 50% of deaths in CKD patients. For this reason, patients with CKD should be thoroughly evaluated for cardiovascular risk factors that require careful management, given the significant burden of CRS type 4 on the healthcare sys…

medicine.medical_specialty030232 urology & nephrologyRenal functionCardiorenal syndromeDisease030204 cardiovascular system & hematologyurologic and male genital diseasesLeft ventricular hypertrophyAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular risk; Chronic kidney disease; Hypertension; Left ventricular hypertrophy; Atherosclerosis; Cardio-Renal Syndrome; Disease Progression; Humans; Hypertension; Hypertrophy Left Ventricular; Renal Dialysis; Renal Insufficiency Chronic; Risk Factors; Internal Medicine03 medical and health sciences0302 clinical medicineRenal DialysisRisk FactorsInternal medicineChronic kidney diseaseCardiorenal syndrome type 4medicineInternal MedicineHumansIn patientRenal InsufficiencyRenal Insufficiency ChronicRisk factorChronicIntensive care medicineCardio-Renal Syndromebusiness.industryLeft ventricular hypertrophyHypertrophymedicine.diseaseAtherosclerosisCardiovascular riskAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular riskLeft VentricularRenocardiac SyndromeAtherosclerosiHypertensionCardiologyDisease ProgressionHypertrophy Left VentricularbusinessKidney disease
researchProduct

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Surve…

2018

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF,…

MalePROGNOSISHypertension Left Ventricular Hypertrophy Atrial FibrillationRHYTHM-CONTROL THERAPYBlood PressureComorbidity030204 cardiovascular system & hematologyLeft ventricular hypertrophy0302 clinical medicineHeart RateRisk FactorsAtrial FibrillationRegistries030212 general & internal medicineStrokeRISKmedicine.diagnostic_testIncidencePULSE PRESSUREWOMENAtrial fibrillationMiddle AgedPulse pressureEuropeSurvival RateEchocardiographyPopulation SurveillanceHypertensionDisease ProgressionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicineSTROKEmedicine.medical_specialtyCANADIAN REGISTRY03 medical and health sciencesAge DistributionInternal medicinemedicineHumansCOHORTcardiovascular diseasesSex DistributionRisk factorRetrospective Studiesbusiness.industryOdds ratiomedicine.diseaseComorbidityATHEROSCLEROSISElectrocardiography AmbulatorybusinessFOLLOW-UPElectrocardiographyFollow-Up Studies
researchProduct

Identification of cardiac organ damage in arterial hypertension: insights by echocardiography for a comprehensive assessment

2020

: Arterial hypertension, a widespread disease, whose prevalence increases with age, represents a major risk factor for cardiovascular events, causing damage in several organs, including the heart. In this context, echocardiography has a clear and pivotal role, being able to assess cardiac morphology and detect haemodynamic changes induced by this disease. 2018 European Society of Cardiology/European Society of Hypertension guidelines on AH identified main echo parameters such as left ventricular mass, relative wall thickness and left atrial volume, for detecting cardiac organ damage. The present review highlights the advantage of additional echocardiographic parameters such as diastolic mea…

Aortic valvemedicine.medical_specialtyarterial hypertensionPhysiologyHeart VentriclesDiastoleHemodynamicsContext (language use)Speckle tracking echocardiographyRegurgitation (circulation)030204 cardiovascular system & hematologyarterial hypertension; cardiac organ damage; diastolic dysfunction; echocardiography; left ventricular hypertrophy03 medical and health sciences0302 clinical medicinecardiac organ damageInternal medicineInternal MedicineMedicineHumans030212 general & internal medicineRisk factorbusiness.industrymedicine.diseasePrognosisleft ventricular hypertrophyStenosismedicine.anatomical_structureEchocardiographyAortic ValveHypertensionCardiologydiastolic dysfunctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Oxidant stress and endothelial activation in hypertensive patients with and without left ventricular hypertrophy

2006

Oxidant stress endothelial activation hypertension left ventricular hypertrophy
researchProduct

Fetuin-A and left ventricular hypertrophy in essential hypertension.

2007

Fetuin-A left ventricular hypertrophy hypertension.
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct